.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX23_Ibalizumab.Ibalizumab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX23_Ibalizumab.Ibalizumab| name: | Ibalizumab |
| ATC code: | J05AX23 | route: | intravenous |
| n-compartments | 2 |
Ibalizumab is a humanized IgG4 monoclonal antibody used as an antiretroviral for the treatment of multidrug-resistant HIV-1 infection in adults. It acts as a post-attachment inhibitor by binding to domain 2 of the CD4 receptor on T-cells, thereby preventing HIV from entering cells. It was approved by the FDA in 2018 and is currently used in clinical practice for patients with limited treatment options due to resistance.
Pharmacokinetic parameters were evaluated in HIV-1-infected adults, both male and female, receiving standard dosing of ibalizumab intravenous infusion (initial 2000 mg loading dose followed by 800 mg every two weeks).
Beran, C, et al., & Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40(4) 194–201. DOI:10.1177/87551225241259894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39157636